129 related articles for article (PubMed ID: 37310065)
61. MUC1 induces the accumulation of Foxp3
Zhang G; Zheng G; Zhang H; Qiu L
Int Immunopharmacol; 2023 May; 118():110091. PubMed ID: 37018979
[TBL] [Abstract][Full Text] [Related]
62. [Gallbladder and bile duct carcinoma. Biology and pathology].
Tannapfel A; Wittekind C
Internist (Berl); 2004 Jan; 45(1):33-41. PubMed ID: 14735242
[TBL] [Abstract][Full Text] [Related]
63. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
Nakazawa K; Dobashi Y; Suzuki S; Fujii H; Takeda Y; Ooi A
J Pathol; 2005 Jul; 206(3):356-65. PubMed ID: 15892172
[TBL] [Abstract][Full Text] [Related]
64. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
65. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling.
Frampton G; Coufal M; Li H; Ramirez J; DeMorrow S
Exp Cell Res; 2010 May; 316(9):1465-78. PubMed ID: 20347808
[TBL] [Abstract][Full Text] [Related]
66. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways.
Prakobwong S; Gupta SC; Kim JH; Sung B; Pinlaor P; Hiraku Y; Wongkham S; Sripa B; Pinlaor S; Aggarwal BB
Carcinogenesis; 2011 Sep; 32(9):1372-80. PubMed ID: 21325634
[TBL] [Abstract][Full Text] [Related]
67. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.
Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W
Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328
[TBL] [Abstract][Full Text] [Related]
68. ASO Author Reflections: Is Systemic Immune-Inflammation Index a Useful Biomarker After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium.
Toyoda J; Sahara K; Endo I; Pawlik TM
Ann Surg Oncol; 2022 Nov; 29(12):7615-7616. PubMed ID: 35776259
[No Abstract] [Full Text] [Related]
69. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
70. Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma.
Sang H; Li T; Li H; Liu J
PLoS One; 2013; 8(11):e81347. PubMed ID: 24312291
[TBL] [Abstract][Full Text] [Related]
71. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
72. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm.
Nakanishi Y; Zen Y; Kondo S; Itoh T; Itatsu K; Nakanuma Y
Hum Pathol; 2008 Aug; 39(8):1153-61. PubMed ID: 18495210
[TBL] [Abstract][Full Text] [Related]
73. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
74. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
75. Calcium-sensing receptor promotes tumor proliferation and migration in human intrahepatic cholangiocarcinoma by targeting ERK signaling pathway.
Fang Y; Liu L; Liu S; Hu L; Cai W; Wan X; Liu D; He Y; Zhu Z
Eur J Pharmacol; 2020 Apr; 872():172915. PubMed ID: 31926993
[TBL] [Abstract][Full Text] [Related]
76. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
77. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis.
Zen Y; Sasaki M; Fujii T; Chen TC; Chen MF; Yeh TS; Jan YY; Huang SF; Nimura Y; Nakanuma Y
J Hepatol; 2006 Feb; 44(2):350-8. PubMed ID: 16360234
[TBL] [Abstract][Full Text] [Related]
78. Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis.
Cui XD; Lee MJ; Kim JH; Hao PP; Liu L; Yu GR; Kim DG
Hepatology; 2013 Jun; 57(6):2248-60. PubMed ID: 23315987
[TBL] [Abstract][Full Text] [Related]
79. CD10+ fibroblasts are more involved in the progression of hilar/extrahepatic cholangiocarcinoma than of peripheral intrahepatic cholangiocarcinoma.
Nishihara Y; Aishima S; Hayashi A; Iguchi T; Fujita N; Taketomi A; Honda H; Tsuneyoshi M
Histopathology; 2009 Oct; 55(4):423-31. PubMed ID: 19817893
[TBL] [Abstract][Full Text] [Related]
80. Intrahepatic cholangiocarcinoma arising 10 years after the excision of congenital extrahepatic biliary dilation.
Goto N; Yasuda I; Uematsu T; Kanemura N; Takao S; Ando K; Kato T; Osada S; Takao H; Saji S; Shimokawa K; Moriwaki H
J Gastroenterol; 2001 Dec; 36(12):856-62. PubMed ID: 11777216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
